NT-proBNP with the cobas h 232 POC system
To support diagnosis and long-term management of Heart Failure (HF)
Use as an initial diagnostic test
In association with clinical evaluation,* NT-proBNP can support decision-making in HF diagnosis in acute and non-acute
settings.9
- Exclude HF and avoid unnecessary echocardiography17-19
- Identify patients with high probability of having HF and need further investigation9
- In primary care, identify patients who need referral to the specialist17-
Use to monitor disease
- Changes in NT-proBNP levels provide important prognostic information to help identify patients at risk of hospitalisation for HF and mortality.
- Monitoring NT-proBNP levels helps to manage HF well over the long term, regardless of symptoms or medication being taken, in particular angiotensin receptor-neprilysin inhibitors (ARNis).
NT-proBNP cut-off levels (pg/mL)
Available tests
The cobas h 232 POC system allows rapid and easy determination of Troponin T, NT-proBNP, D-Dimer, CK-MB and Myoglobin in different settings, like ambulances, general practitioner offices and emergency rooms.
Test |
Measuring range |
Time to result |
Clinical utility |
Troponin |
40 – 2,000 ng/L | 12 min | Early aid in diagnosis of acute myocardial infarction and identification of patients with an elevated mortality risk4 |
NT-proBNP |
60 – 9,000 pg/mL | 12 min | Aid in diagnosis of patients with suspected heart failure, in monitoring of patients with compensated left ventricular dysfunction and in the risk stratification of patients with acute coronary syndromes5 |
CK-MB |
1.0 – 40 ng/mL | 12 min | Aid in diagnosis of patients with suspected acute myocardial infarction (AMI, heart attack), assessment of the size of the infarction and detection of re-infarction1 |
D-Dimer |
0.1 – 4.0 µg/mL | 8 min | Aid in exclusion of deep venous thrombosis and pulmonary embolism2 |
Myoglobin |
30 – 700 ng/mL | 8 min | Aid in diagnosis of patients with suspected myocardial infarction, reperfusion control3 |
References
1 Bertsch, T. et al. (2010). Clin Lab. 56(1-2), 37-49.
2 Roche (2016). cobas h 232 POC system Operator’s Manual, Version 6.0.
3 Roche CARDIAC D-Dimer-Method Sheet-package insert.
4 Roche CARDIAC proBNP-Method Sheet-package insert.
5 Roche CARDIAC POC Troponin T-Method Sheet-package insert.
6 Roche CARDIAC CK-MB-Method Sheet-package insert.
7 Roche CARDIAC M-Method Sheet-package insert.
8 Konstantinides, S. et al. (2014). Eur Heart J 35, 3033-3080.
9 Ponikowski, P. et al. (2016). Eur J Heart Fail 18(8), 891-975.
10 Roffi , M. et al. (2015). Eur Heart J 37(3), 267-315.
11 Stengaard, C. et al. (2013). American J Cardiol 112(9), 1361-1366.
12 Achar, S.A. et al. (2005). Am Fam Physician 72(1), 119-126.
13 Jungbauer, C. et al. (2017). Clin Lab 63(4), 633-645.
14 De Bastos, M.M. et al. (2008). Blood Coagul Fibrinolysis 19(1),
48–54.
15 Wells, P.S. et al. (2003). N Engl J Med 349(13), 416-420.
16 Berliner, D. et al. (2016). Dtsch Arztebl Int 113(49), 834-845.
17 Taylor, C.J. et al. (2017). Br J Gen Pract. 67(655), e94-e102.
18 Taylor, C.J. et al. (2017). Effi cacy and Mechanism Evaluation, No. 4.3. National Institute for Health. Research. ISSN 2050-4365. [Accessed September 2018].
19 British Heart Foundation and the All-Party Parliamentary Group on Heart Disease (2016). Focus on Heart Failure. Report accessible on https://www.bhf.org.uk/get-involved/campaigning/inquiry-
intoliving-with-heart-failure [Accessed September 2018].
20 Januzzi, J.L. et al. (2006). Eur Heart J 27(3), 330-337.
21 Januzzi, J.L. et al. (2018). J Am Coll Cardiol 71(11), 1191-1200.
22 Masson, S. et al. (2008). J Am Coll Cardiol 52, 997-1000.
23 DeBeradinis, B., Januzzi, J.L. (2012). Curr Opin Cardiol 27(6):
661-668.
24 Chiong, J. (2010). Heart Fail Rev. 15(4), 275-291.
25 Weiner, R. (2012). Eur J Heart Fail 15(3), 342-351.
26 Januzzi (2012). Arch Cardiovasc Dis. 105(1), 40-50.
27 Januzzi, J.L. et al. (2016). Clin Chem 62(5), 663-665.
28 Stengaard, C. et al. (2016). European Heart Journal: Acute Cardiovascular Care, 1-10.
